International randomized phase II trial of the combination of Vincristine and Irinotecan with or without Temozolomide (VI or VIT) in children and adults with refractory or relapsed rhabdomyosarcoma.
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Temozolomide (Primary) ; Irinotecan; Vincristine
- Indications Rhabdomyosarcoma
- Focus Therapeutic Use
- 19 Jul 2017 Planned End Date changed from 31 Dec 2021 to 1 Sep 2021.
- 15 Mar 2017 Planned End Date changed from 1 Jun 2015 to 31 Dec 2021.
- 15 Mar 2017 Status changed from completed to recruiting.